Triple-Drug attack shows promise against multiple myeloma
NCT ID NCT02441686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 study tested a combination of three drugs—lenalidomide, bortezomib, and dexamethasone (RVD)—in 46 people newly diagnosed with multiple myeloma. The goal was to see how well the drugs worked before a stem cell transplant. The study measured response rates and side effects like nerve damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide, bortezomib, and dexamethasone (RVD combination)
What this could lead to
If successful, this combination could become a standard initial treatment for newly diagnosed multiple myeloma, improving response rates before stem cell transplant.
What could go wrong
This is a small Phase 2 trial with only 46 participants, so results may not apply to all patients. Side effects like nerve damage are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
Hematology Oncology of Northern New Jersey
Morristown, New Jersey, 07962, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02114, United States
-
Virgina Piper Cancer Institute
Minneapolis, Minnesota, 55407, United States
-
Virginia Piper Cancer Institute
Coon Rapids, Minnesota, 55433, United States